Content about Platinum compounds

August 9, 2012
Hospira relaunches chemotherapy drug

Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.

LAKE FOREST, Ill. — Hospira has relaunched a generic chemotherapy drug for the U.S. market, the generic drug maker said Thursday.

The company, which specializes in generic injectables, announced the relaunch of oxaliplatin, a version of Sanofi's Eloxatin.

August 9, 2012
Sagent Pharmaceuticals launches oxaliplatin

Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

Sagent announced the launch of oxaliplatin, a generic version of Sanofi's Eloxatin.

Various versions of the drug had sales of about $1.7 billion during the 12-month period ended in June, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

February 9, 2011
Genentech: Avastin boosts chances of progression-free survival among ovarian cancer patients

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.

December 8, 2010
Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

BURLINGTON, Mass. — Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

October 25, 2010
Suspending oxaliplatin sales leads to loss for Hospira

The temporary discontinuation of sales of a drug used by cancer patients led to a...

LAKE FOREST, Ill. The temporary discontinuation of sales of a drug used by cancer patients led to a slight dip in sales for Hospira during third quarter 2010, but the company nonetheless had strong sales overall, according to an earnings report released Tuesday.